Clinical trials: Overweight, Obesity
Schizophrenia, Schizoaffective Disorder
Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
The purposes of this study are to determine: The effectiveness of olanzapine as compared to quetiapine in treating and preventing the recurrence of a variety of symptoms of schizophrenia and schizoaffective disorder in patients…
- Trial name
- NCT00090012
- Testing
- Olanzapine, Quetiapine
- Where
- 25 sites in United States
- Volunteers
- 340 people
- Sponsor
- Eli Lilly and Company
Obesity
Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)
Study medicine will be given alone, or in combination with either sibutramine or orlistat, to obese subjects to compare the effect on body weight over a six month period.
- Trial name
- NCT00533481
- Testing
- MK0557
- Volunteers
- 497 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity
Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.
This is a non-interventional study to evaluate the safety and effectiveness of Saxenda® in obese adults and adolescents in Taiwan.
- Trial name
- NCT06283641
- Testing
- Liraglutide
- Where
- 15 sites in Taiwan
- Volunteers
- 300 people
- Sponsor
- Novo Nordisk A/S
Obesity, Dyslipidemia
Obese Patients With Untreated Dyslipidemias
To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with untreated dyslipidemia
- Trial name
- RIO-Lipids (NCT00029835)
- Testing
- Rimonabant (SR141716)
- Where
- 35 sites in United States, Australia and 6 more
- Volunteers
- 1,033 people
- Sponsor
- Sanofi
Metabolism and Nutrition Disorder, Obesity
Awareness, Care & Treatment in Obesity Management (ACTION) Study
The ACTION (Awareness, Care, and Treatment In Obesity management) study aims to identify perceptions, attitudes, behaviours, and potential barriers to effective obesity care across three respondent types: 1) People with Obesity…
- Trial name
- ACTION (NCT03223493)
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 3,767 people
- Sponsor
- Novo Nordisk A/S
Overweight and Obese Volunteers
Evaluate LAE102 in Healthy and Overweight/Obese Subjects
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE102 injection in healthy and overweight/obese participants, and also evaluate the preliminary pharmacodynamic effect of multiple dose…
- Trial name
- NCT06493084
- Testing
- LAE102 intravenous administration, LAE102 subcutaneous administration, LAE102 multiple subcutaneous administration
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Laekna Limited
Obstructive Sleep Apnea (OSA) and Obesity
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) Therapy
This is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy and safety of the HDM1005 in patients with obstructive sleep apnea (OSA) and obesity receiving positive airway pressure (PAP)…
- Trial name
- NCT07794397
- Testing
- HDM1005
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Text Messaging (Intervention), Control
Text4Diet: A Text Messaging Program for Weight Loss
The purpose of the present RCT is to evaluate a 12-month SMS intervention with expanded content, intervention strategies and interactive database logic, novel online enrollment, and automatic baseline scoring of measures to…
- Trial name
- Text4Diet (NCT01571258)
- Testing
- Text Messaging
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Santech, Inc
Obesity
A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study: To evaluate the efficacy of different dose levels of CX11 tablets in body weight reduction as compared to placebo.
- Trial name
- NCT07011797
- Testing
- CX11
- Where
- 17 sites in United States
- Volunteers
- 250 people
- Sponsor
- Corxel Pharmaceuticals
Healthy Participants, Type 2 Diabetes
A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Japanese Participants and Participants With Type 2 Diabetes Mellitus
This Phase I study will gather important information on the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5004 in both healthy Japanese participants and Japanese participants with T2DM.
- Trial name
- NCT06703658
- Testing
- AZD5004(Part A), AZD5004(Part B)
- Where
- Japan
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Overweight and Obesity, Weight Loss
Study to Evaluate Effects of a Weight Loss Program in Different Formats on Healthy Adults
The objective of this study was to determine changes in body weight and related outcomes achievable over a 16-week period in response to three different commercially available weight loss programs (Nutrisystem) providing…
- Trial name
- NCT03017443
- Testing
- Nutrisystem Turbo 10, Nutrisystem My Way, Nutrisystem DASH
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Nutrisystem, Inc.
Type 2 Diabetes Mellitus With Circulatory Complciation
Neurotronic Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities
The study is to assess the safety and feasibility of chemical denervation of multiple artery beds for the treatment of Type 2 diabetes (T2DM) and its comorbidities.
- Trial name
- NECTAR (NCT04232774)
- Testing
- The Neurotronic arterial ablation catheter
- Where
- Paraguay
- Volunteers
- 22 people
- Sponsor
- Neurotronic, Inc.
Obesity
A Trial of HRS-5817 in Obese Participants
The purpose of this study is to assess safety, PK, Pharmacodynamic and immunogenicity profile of a single dose of HRS-5817 in obese participants
- Trial name
- NCT07238647
- Testing
- HRS-5817
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Atridia Pty Ltd.
Overweight or Obesity
Effect of Akkermansia Muciniphila Akk11 on Metabolic and Gut Health in Overweight and Obese Subjects
To assess the efficacy and safety of the use of probiotics as a food supplement compared to placebo in regulating body metabolism and gut microbiota in overweight or obese subjects.
- Trial name
- NCT06653101
- Testing
- Probiotic
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America. The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese…
- Trial name
- NCT01272219
- Testing
- liraglutide
- Where
- 226 sites in United States, Argentina and 27 more
- Volunteers
- 3,731 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
- Trial name
- TRIUMPH-8 (NCT07232719)
- Testing
- Retatrutide
- Where
- 31 sites in United States, United Kingdom
- Volunteers
- 250 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes.
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- NCT06993792
- Testing
- Orforglipron
- Where
- 80 sites in United States, Argentina and 5 more
- Volunteers
- 1,400 people
- Sponsor
- Eli Lilly and Company
Cardiovascular Risk, Obesity
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
This clinical study is being conducted to evaluate the safety and effectiveness of zenagamtide in people with atherosclerotic cardiovascular disease (ASCVD) and excess body weight compared with placebo.
- Trial name
- AMBIENCE (NCT07861100)
- Testing
- Zenagamtide
- Where
- 769 sites in United States, Argentina and 24 more
- Volunteers
- 8,500 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.
- Trial name
- NCT06313528
- Testing
- LY3437943
- Where
- 3 sites in United States
- Volunteers
- 85 people
- Sponsor
- Eli Lilly and Company
Healthy
A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants
The purpose of the study was to understand the effect of PF-07081532 on the movement of Dabigatran and Rosuvastatin into, though, and out of the body in healthy overweight or obese adult participants.
- Trial name
- NCT05788328
- Testing
- Dabigatran etexilate (DE), Rosuvastatin, PF-07081532
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.